Pt Soho Global Health Tbk · IDX:SOHO
Pt Soho Global Health Tbk — SOHO Global Health — Investor Presentation (April 2026)
46 slides from Pt Soho Global Health Tbk's investor presentation, April 2026
Slide 1: Company Presentation April 2026
Company Presentation Ap r i l 2 0 2 6 STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer This presentation is made available on the Company’s website for general information purposes and to ensure equal access to information for all shareholders and stakeholders. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a ci
Slide 3: Agenda
1 Introducing SOHO Global Health 2 Business highlights Agenda 3 Financials overview 4 Appendix (Strategies) 5 Appendix (Financials) 3
Slide 4: Introducing SOHO Global Health
1 Introducing SOHO Global Health 4
Slide 5: Today's presenters
Today’s presenters Rogelio Paulino Jr. Piero Brambati Yuliana Pandy Harianto Andreas Ardhika Castillo Lao Antoninus CEO CFO & COO Chief Legal, HR & COO Head of Marketing - Commercial Corporate Secretary - Operations & International Business Consumer Health 5
Slide 6: SOHO at a glance
at a glance Who we are 95% Healthcare distribution 28 coverage6 ~10x Consumer health Online revenue #1 Consumer health brands and growing4 155k+ Presence growth8 brands across segments in 59 marketed across channels7 14% vs 2% / under registration Online contribution Indonesia1 pharma molecules5 (FY
Slide 7: Our key business segments
Our key business segments CONSUMER HEALTH ALLIANCE DISTRIBUTION Nationwide distribution enabling Trusted, high-quality preventative, In-licensing of global prescription owned product prioritisation curative & wellness products to pharmaceutical products while providing 3rd party services support eve
Slide 8: Business highlights
SOHO Global Health Business highlights
Slide 9: Key business highlights and strategies
Key business highlights and strategies Legend SOHO CH - Consumer Health AL - Alliance DIST - Distribution Business highlights Strategies SOHO - Category leader in high-growth Vitamins and A CH - Drive market share 1 accretion in an already fast- Skincare market, poised to capture Indonesia upside gr
Slide 10: Category leader in high-growth Vitamins and Skincare, poised to capture Indonesia upside
SOHO – Category leader in high-growth Vitamins and Skincare, poised to capture Indonesia upside 1 Category leading pharma and consumer healthcare company, poised for growth amidst a highly attractive Indonesia market backdrop … Strong growth potential in Indonesia’s vitamins and skincare market, und
Slide 11: Indonesia moves up the health and wellness spending curve
SOHO – Category leader in high-growth Vitamins and Skincare, poised to capture Indonesia upside 1 … with significant opportunities as Indonesia moves up the health and wellness spending curve Indonesia exhibits among the lowest healthcare spending per capita levels in … alongside the region’s lowest
Slide 12: Market leading brands with strong equity and category leadership
CH – Market leading brands with strong equity and category leadership 2 SOHO is a leading consumer healthcare company with multiple category leading brands Indonesia’s leading consumer healthcare company with iconic #1 #1 #1 brands and a diversified Vitamin Vitamin Fastest growing company1 brand1 ph
Slide 13: Core brands extended across therapeutic categories and age groups
CH – Market leading brands with strong equity and category leadership 2 Backed by strong brand equity, SOHO has consistently extended its core brands across therapeutic categories and age groups Immune defense Imboost Extra Vit Imboost Bone Imboost Cough Imboost Cough Imboost Imboost Kids Imboost Ki
Slide 14: Fast scaling digital and e-commerce engine driving omni-channel lift
CH – Fast scaling digital and e-commerce engine driving omni-channel lift 3 Dedicated, fully in-house digital marketing capabilities that have driven compelling results and omnichannel momentum Early proof points… 100k new posts/month 1 SOHO monthly revenue from online channels (IDRbn) 35 Online con
Slide 15: Alliance: growth driver with in-licensing business model
AL – Strategically curated in-licensing portfolio 4 Alliance is another proven growth driver, with attractive opportunities in its own-branded, in-licensed business model Indonesia’s drug market is rapidly growing but continues to have a number of underserved needs ⚫ Lack of market insights constrai
Slide 16: Proven in-licensing model, illustrated by Pramifrol ER
AL – Strategically curated in-licensing portfolio 4 A proven in-licensing model, illustrated by Pramifrol ER and scaled across a diversified product portfolio PRAMIFROL ER DARZALEX FASPRO MYCOPHEN Treatment of Prevention of multiple organ Treatment of Parkinson’s myeloma rejection3 disease EPCLUSA D
Slide 17: Systematic new product development process
CH/AL – Strong product development, powered by robust R&D and world-class manufacturing facility 5 Systematic new product development process that can be consistently replicated to create market leading brands… With a systematic development process… Product Understand 1 customers 2 Idea generation 3
Slide 18: World-class manufacturing facilities with limited incremental capex
CH/AL – Strong product development, powered by robust R&D and world-class manufacturing facility 5 … through world-class manufacturing facilities with limited incremental capex required, supported by relevant certifications Liquid mixing Capabilities 25,378 sqm Manufacturing operations Liquid fillin
Slide 19: Nationwide distribution network powered by proprietary PPGOS 3.0
DIST – Highly effective sales and distribution network, serving as a key enabler for growth 6 Nationwide distribution network powered by proprietary PPGOS 3.0 that provides service differentiation and advanced features Powered by proprietary tech PPGOS 3.0 Nationwide distribution network with reliab
Slide 20: Professional management team with blue-chip track record
SOHO – Professional management team with blue chip track record, operating under world-class compliance & governance framework 7 Professional management team with blue-chip track record 20 – 37+ years of relevant experience across >37 >26 >20 senior management Rogelio Paulino Piero Brambati Yuliana
Slide 21: Fully compliant operations and governance standards
SOHO – Professional management team with blue chip track record, operating under world-class compliance & governance framework 7 Fully compliant operations & governance standards that enables sustainable growth ⚫ Anchored in five GCG principles Strong ⚫ Guided by a formal GCG code Strong focus on su
Slide 22: Increasing focus on high margin segments to unlock shareholder value
SOHO – Strong financial profile with topline growth and margin expansion 8 Increasing focus on high margin segments to unlock better shareholders’ value Legend Total Consumer Health Alliance Distribution 2023-25 CAGR 1,000 900 800 795 / 7.4% 28% 700 621 / 6.2% 224 / 2.4% EBITDA1,2 600 15% 487 / 5.9%
Slide 23: Financials overview
SOHO Global Health Financials overview
Slide 24: Segment breakdown
Segment breakdown Segmental performance reflects strong growth and margin expansion Key financials by segment from FY2023-25 (IDR billions / %) (In IDRbn) Consumer health Alliance Distribution Others2 Revenue1 CAGR: 21.1% CAGR: 29.0% CAGR: 14.1% CAGR: (10.4%) 8,872 9,333 7,170 1,151 785 924
Slide 25: EBITDA bridge and NPAT growth
EBITDA bridge and NPAT growth EBITDA uplift is mainly driven by shift to higher margin segments, supported by operational efficiency improvements, leading to growth in net profit along with margin expansion EBITDA bridge from FY2023-25 (IDR billions) EBITDA CAGR (FY2023-25): 27.8% Margin 5.9% 7.4%
Slide 26: Appendix (Key Strategies)
4 Appendix (Key Strategies) 26
Slide 27: Key strategies
Key strategies A Consumer Health B Consumer Health C Alliance D Distribution E SOHO Drive market Build on digital Solid incremental Further optimize Drive group-wide share accretion in capabilities to momentum from our Distribution operational an already fast- drive growth in Alliance to platform th
Slide 28: Curated portfolio expansion leveraging existing brand equities
CH – Drive market share accretion in an already fast-growing consumer health market A Curated portfolio expansion, leveraging existing brand equities and creating new winners... Online sales growth2: 2.2x Online sales contribution3: 5% Track record of successful launches… …with a robust upcoming pip
Slide 29: Driving SOHO's market share in a fast growing market
CH – Drive market share accretion in an already fast-growing consumer health market A ...driving SOHO's market share in an already fast growing and attractive market Overview of vitamins and supplements market in Indonesia1 Key highlights Online channel Offline channel Market share ⚫ Consistently le
Slide 30: Strategic build out of digital capabilities
CH – Build on digital capabilities to drive growth in online and offline channels B Strategic build out of digital capabilities on the back of key guiding principles with measurable near-term objectives Leverage digital Guiding principles Expansion of digital native Enhancement of content capabiliti
Slide 31: Digital presence as a demand generation layer
CH – Build on digital capabilities to drive growth in online and offline channels B To build digital presence as a demand generation layer that converts to both online and offline purchases Digital as a demand generation layer across online and offline channel Content-led education builds Engagement
Slide 32: Asthin case study in O2O marketing
CH – Build on digital capabilities to drive growth in online and offline channels B Proven case study with Asthin illustrates SOHO’s track record in executing O2O marketing strategy Dec-25 monthly sales was 4.9x of Q1 2024 average monthly sales: ⚫ Dec-25 online only monthly sales was 2.6x of Q1 2024
Slide 33: Case studies with Curcuma Plus, Noroid, and Fitkom
CH – Build on digital capabilities to drive growth in online and offline channels B Proven case studies with Curcuma Plus, Noroid, and Fitkom illustrate SOHO’s track record in executing O2O marketing strategy Online channels Offline channels Online channels Offline channels Online channels Offline c
Slide 34: Business Development focus to drive in-licensing growth
AL – Solid incremental momentum from Alliance to turbocharge our highly profitable growth C Concerted Business Development focus, sharpened by leveraging data and partner insights, to drive growth in our in-licensing business Continued business 1 Data-driven molecule identification by PPG intel and
Slide 35: Optimizing the Distribution platform
DIST – Further optimize our Distribution platform through sharpening our mix, reach and profitability D Capturing low hanging wins to set up our Distribution platform for optimal effectiveness and overall earnings accretion Continue to ⚫ Develop PPGOS as a core capability to strengthen customer stic
Slide 36: Further improvements for operational excellence and efficiency
SOHO – Drive group-wide operational excellence and efficiency E Further improvements for operational excellence and efficiency leading to Margin ROCE Guiding principles improvement and Improvements cost efficiency Key focus areas Capital Headcount General expense Unit economics efficiency ⚫ Boost pr
Slide 37: Appendix (Financials)
SOHO Global Health Appendix (Financials)
Slide 38: Revenue mix by segment and sales channel
Revenue mix by segment and sales channel Diversified revenue streams across segments and channels underpin stable growth Revenue mix from FY2023-25 (IDR billions / %) Financial year ending 31 Dec FY2023 FY2024 FY2025 Revenue (IDR billions) 8,198 10,058 10,779 YoY growth (%) 12% 23% 7% Distributio
Slide 39: Operating cost structure
Operating cost structure Sustainable and disciplined cost structure enables economies of scale and operating leverage Operating expenses breakdown from FY2023-25 (IDR billions / %) 1,082 970 871 345 333 309 336 Sales employee expenses 290 252 Advertising & promotion 347 401 Other operating expenses
Slide 40: Working capital overview
Working capital overview Working capital optimization via improving inventory turnover and extending supplier terms, offsetting higher receivables and reducing the cash conversion cycle from 37 days in FY 2023 to 24 days in FY 2025 Trade receivables turnover1 (days) Inventory turnover2 (days) Trade
Slide 41: Strong free cash flow with significant capacity headroom
Strong free cash flow with significant capacity headroom Robust free cash flow generation, supported by utilization rates that indicate ample runway for future growth without material incremental capital expenditure Free cash flow1 (IDR billions/ Conversion rate2 %) Asset-light operating model Capit
Slide 42: Shareholder returns analysis
Shareholder returns analysis Attractive shareholder returns underpinned by return on equity and dividend discipline Return on equity1 (%) Dividend payout ratio2 (%) 107.7% 21.8% 17.0% 15.5% 50.1% 32.9% 1 FY2023 FY2024 FY2025 FY2023 FY2024 FY2025 Delivers consistently strong ROE reflecting efficient
Slide 43: Historical income statement
Historical income statement Income statement from FY 2023 to 2025 Financial year ending 31 December, in IDR millions 2023 2024 2025 Net Revenues 8,197,755 10,057,938 10,779,187 Cost of Revenues (6,888,399) (8,517,100) (8,974,751) Gross Profit 1,309,356 1,540,838 1,804,435 Selling expenses (714,610)
Slide 44: Historical balance sheet
Historical balance sheet Balance sheet as at end of FY 2023 to 2025 Financial year ending 31 December, in IDR millions 2023 2024 2025 Cash and cash equivalents 688,466 422,446 1,104,126 Trade receivables – third parties, net 1,456,108 1,851,763 1,987,071 Other receivables – third parties, net 236,97
Slide 45: Historical balance sheet (cont'd)
Historical balance sheet (cont’d) Balance sheet as at end of FY 2023 to 2025 Financial year ending 31 December, in IDR millions 2023 2024 2025 Trade payables – third parties 1,907,093 2,213,493 2,638,441 Other payables – third parties 82,685 77,121 509,359 Taxes payable 11,410 24,893 34,984 Accrued
Slide 46: Historical cash flow statements
Historical cash flow statements Cash flow statement from FY 2023 to 2025 Financial year ending 31 December, in IDR millions 2023 2024 2025 Cash receipts from customers 7,952,799 9,662,283 10,643,879 Cash payments to suppliers (6,834,051) (8,442,528) (8,489,447) Cash payments for salaries, wages, and
SOHO Global Health — Investor Presentation (April 2026) on 6ix